Please login to the form below

Not currently logged in
Email:
Password:

In the Wild

This page shows the latest In the Wild news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

However, the updated results revealed what might be a dose-dependent increase in the risk of arthropathy with the drug. ... view the candidates still in trials as wild cards, potentially offering big rewards but also a having a high risk of failure.

Latest news

  • NICE backs BMS' Opdivo for melanoma NICE backs BMS' Opdivo for melanoma

    We welcome [the] decision from NICE, which is positive news for melanoma patients in the UK," said Johanna Mercier, general manager of BMS in the UK and Ireland. ... approval. The green light means that the cancer immunotherapy combination can be used in

  • New behavioural science comms consultancy launches New behavioural science comms consultancy launches

    In the Wild's managing director Andrew Martello said: “Our clients are innovators in the pharmaceutical industry who see the untapped potential of behavioural science. ... Brighton, UK-based consultancy In the Wild says it will focus on creating

  • Erbitux betters Avastin in bowel cancer subgroup Erbitux betters Avastin in bowel cancer subgroup

    However, new data presented at the Congress suggests that Merck's drug may be superior in the subset of patients with RAS wild-type mCRC – a form of mCRC associated with ... overall survival and may in part explain why we are seeing the overall

  • Information seen as main future health issue

    A forum headed by WPP has highlighted 'information proliferation' as the main issue in the future of healthcare in the EU. ... In all sessions, however, the most pressing matter in information proliferation was that it was 'in the wild'.

  • Tamiflu boosts Roche sales rise

    Roche is riding high on the back of strong demand for antiviral, Tamiflu, after reporting a 20 per cent rise in third quarter sales to SwFr 10.47bn ($8.23bn), beating ... ìThis is the wild card in the pack, î Roche pharmaceuticals unit head, William

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics